Onconase

Onconase

Experimental oncology
A ribonuclease derived from the oocytes of the frog Rana pipiens, which was in clinical trials for treating mesothelioma.
 
Adverse effects
Anorexia, flushing, vertigo.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

Onconase®

P30 Protein Oncology A ribonuclease-like protein derived from frog–Rana pipiens–embryos, said to be effective against some CAs–eg, mesothelioma. See Unproven methods for cancer management.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
Raines, "Comprehensive comparison of the cytotoxic activities of onconase and bovine seminal ribonuclease," Comparative Biochemistry and Physiology--Part C: Toxicology and Pharmacology, vol.
Donadelli, "Onconase induces autophagy sensitizing pancreatic cancer cells to gemcitabine and activates Akt/mTOR pathway in a ROS-dependent manner," Biochimica et Biophysica Acta--Molecular Cell Research, vol.
Mild hyperthermia predisposes tumor cells to undergo apoptosis upon treatment with onconase. International Journal of Oncology 30:841-847.
and Alfacell Corporation have entered into an exclusive licensing agreement under which Strativa has acquired the commercialization rights in the United States and its territories to ONCONASE (ranpirnase) from Alfacell.
Strativa will also make a payment to Alfacell of up to $30 million upon FDA approval of ONCONASE. In addition to royalties on sales, Alfacell may receive milestone payments on future sales.
ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology.
SciTech21-20 December 2006-Alfacell Corp., GENESIS Pharma Announce Licensing Agreement for ONCONASE in Southeast Europe(C)2006 JeraOne - http://www.jeraone.com
for the commercialization of ONCONASE (ranpirnase), the company's lead drug candidate for unresectable malignant mesothelioma (UMM).
The fusion protein consists of ONCONASE (ranpirnase) and a humanized anti-CD22 monoclonal antibody.
Rybak stated, "This fusion protein and other new molecular forms of ONCONASE will specifically target tumor cells by attaching to antigens on the cell surface.
Alfacell Corporation (Bloomfield, NJ; 973-748-8082), a leader in the research and development of ribonuclease enzymes with anti-cancer and other therapeutic proper-ties, announced the company has been issued new European Patent 837 878 that covers the amino acid sequence, method of manufacture, and a natural variant of its proprietary drug ONCONASE.
ONCONASE was designated an Orphan Medicinal Product by the European Agency for the Evaluation of Medicinal Products, which is the European counterpart to the United States Food and Drug Administration, in February 2001.